Protalix BioTherapeutics Inc. (PLX) Sees Large Increase in Short Interest
Protalix BioTherapeutics Inc. (NYSE:PLX) was the target of a significant increase in short interest during the month of September. As of September 30th, there was short interest totalling 742,145 shares, an increase of 4.2% from the September 15th total of 712,565 shares. Based on an average daily trading volume, of 58,421 shares, the short-interest ratio is presently 12.7 days. Approximately 0.8% of the company’s stock are short sold.
A number of analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Protalix BioTherapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, September 7th. Jefferies Group dropped their price target on shares of Protalix BioTherapeutics from $1.75 to $0.80 and set a “buy” rating for the company in a research note on Tuesday, September 6th. Finally, Rodman & Renshaw restated a “buy” rating on shares of Protalix BioTherapeutics in a research note on Monday, July 11th.
Shares of Protalix BioTherapeutics (NYSE:PLX) opened at 0.4851 on Wednesday. The firm’s 50-day moving average is $0.59 and its 200 day moving average is $0.71. Protalix BioTherapeutics has a 1-year low of $0.49 and a 1-year high of $1.25. The company has a market cap of $48.39 million and a price-to-earnings ratio of 0.9587.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/protalix-biotherapeutics-inc-plx-sees-large-increase-in-short-interest.html
Protalix BioTherapeutics (NYSE:PLX) last released its quarterly earnings data on Monday, August 8th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by $0.03. The company earned $1.77 million during the quarter, compared to analysts’ expectations of $1.34 million. During the same quarter in the prior year, the company earned ($0.05) EPS. Equities analysts expect that Protalix BioTherapeutics will post ($0.41) EPS for the current fiscal year.
Receive News & Ratings for Protalix BioTherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix BioTherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.